Ningbo Tianyi Medical Appliance Co. Ltd.

Tianyi Medical released its 2026 interim report, with net profit attributable to the parent company of 16.1177 million yuan, up 69.96% from the same period last year. Total operating revenue was 338 million yuan, an increase of 111 million yuan, up 48.81%, achieving four consecutive years of growth. Net cash flow from operating activities was negative 9.6654 million yuan, down 130.32% from the same period last year. The company's latest asset-liability ratio was 53.35%, gross margin was 46.78%, and diluted earnings per share was 0.27 yuan.

Tianyi Medical announced that its wholly-owned subsidiary, Thailand Tianyi, has recently obtained the Medical Device Import Detail Filing Acceptance Certificate for sodium citrate anticoagulant solution from the Thai Ministry of Public Health. This product is indicated for patients undergoing continuous renal replacement therapy who require a sodium citrate anticoagulation regimen, particularly those at high risk of bleeding or with heparin-induced thrombocytopenia.